A comparative study of platelet parameters in end stage renal disease patients undergoing haemodialysis and healthy individuals (original) (raw)
Related papers
2022
Introduction. Mean platelet volume (MPV) is a marker used to assess the platelet' size and is also an indicator of platelet reactivity and prothrombotic status. Objective. In this study, we aimed to determine the relationship between MPV and biochemical parameters in patients who had received hemodialysis (HD) for the first time and then in respect of those same patients after their fourth HD. Method. 151 HD patients were enrolled in this study. Patients were eligible for inclusion if they had received their first HD session during this study protocol. Prehemodialysis blood samples were taken. Most laboratory values, including mean platelet volume (MPV) level and platelets (PLT) count, were measured before the first HD and after the fourth HD session for each patient. Results. Among the patients in our study, the mean age profile of the male patients (n � 103; 68.2%) was found to be higher than that of the female patients (n � 48; 31.8%) (53.62 ± 18.19 vs. 46.17 ± 17.9 years) (p � 0.019).In the patients' laboratory results after the fourth HD session, MPV, MPV/Plt, and Na values had increased to those after the first HD session (p < 0.001). When age and gender status were taken into account, the level of weak positive correlation with white blood cell count (WBC), neutrophil, and red cell distribution width (RDW) was found, while the weak negative correlation with platelet to lymphocyte ratio (PLR) was found (p < 0.001). Conclusions. In our study, we found that increase in MPV and MPV/PLT levels was significant in the fourth HD session of patients with CKD. It is also debatable that there are findings indicating an increase in platelet reactivity in the first weeks of the onset of HD. is could be an early indicator of the early prevention of cardiovascular diseases.
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2017
Introduction: Diabetes mellitus is rapidly growing and almost becoming epidemic, with currently 285 million people with diabetes worldwide. Chronic Kidney Disease (CKD) is evolving to be an important global disease, with diabetes playing a pivotal role behind this rapid outburst of CKD incidence. Aim: To evaluate platelet indices and to study the coagulation profile in haemodialysis patients having Type 2 diabetes with CKD and diabetic patients without CKD.
Platelets Dysfunction in Patients of End Stage Renal Disease
2010
Introduction: Patients with end – stage renal disease (ESRD) develop increased bleeding tendency, which is characterized by defective interaction of platelets with damaged sub endothelium due to impaired platelet functions. This study was carried out to demonstrate the aggregation defects in uraemic patients by using different platelet agonists. Materials and Methods: A total of 57 subjects were included in the study. These were divided into two groups; 37 patients of ESRD on maintenance haemodialysis and 20 healthy adults as control. Complete blood count (CBC), urea and creatinine were carried out on all the samples. Aggregation studies were performed using chronology 490 – 2D Platelet Aggregometer. Adenosine diphosphate (ADP), collagen, ristocetin and arachidonic acid were used as agonists to perform aggregation studies and correlation of these parameters with Haemoglobin (Hb), Haematocrit (Hct), urea and creatinine were determined. Results: All the subjects included in this study...
Aspects of platelet disturbances in haemodialysis patients
Clinical Kidney Journal, 2013
Patients with mild-to-chronic kidney disease (CKD) exhibit a variety of haemostatic disorders, ranging from an increased clotting tendency and reductions in the levels of natural inhibitors of coagulation to defective fibrinolysis. In addition, platelet (PLT) abnormalities are common. In this minireview, we report on aspects of haemodialysis (HD)-induced PLT activation. It is demonstrated that PLTs from HD patients are exhausted due to repeated stimulation of HD treatment and recurrent release of PLT degranulation products. During HD, additional aberrations of the haemostatic process occur. Besides deviations of coagulation and fibrinolysis, PLT activation and a reduction in their granule content have been observed during HD treatment. As HD treatment is carried out three times per week, month after month, chronic HD patients may suffer persistently from coagulation defects and PLT disorders on top of the alterations induced by the uraemic state itself. PLT activation occurs together with thrombin and fibrin generation. However, macro fibrin depositions in clot devices are not demonstrated, microaggregates occur not only in the extracorporeal circuit (ECC) but are also present in the blood circulation. As vascular access thrombosis is a frequent complication in patients with HD treatment, it is believed that hypercoagulability could result from vascular changes combined with PLTs and activation of coagulation factors.
Biomolecular and Health Science Journal, 2018
Introduction: Chronic kidney disease (CKD) is increasing in Indonesia, furthermore, it requires high treatment cost such as conservative therapy and kidney transplantation or dialysis. There are two types of dialysis; hemodialysis (HD) and peritoneal dialysis. The patient who undergoes HD needs periodical laboratories evaluation due to its impact on hemoglobin (Hb), leukocyte and platelets. The purpose of this study was to obtain the levels of Hb, leukocyte and platelets regularly in stage 5 CKD patients undergoing HD. Methods: Data were collected from patients' medical record from October to December 2014 and it was characterized based on age, sex, HD frequency, HD period, hemoglobin, iron saturation, ESA (erythropoiesis-stimulating agent), leukocyte level and platelets level. 60 samples were included with the same ratio. Results: The average of age was 45 years old and the average of HD period was 40 months. All patients suffered anemia, however, only 51 patients could be evaluated the iron saturation. From it, 37 patients had the iron saturation of ≥20% which 14 (38%) of them received ESA. There were 14 patients who suffered zinc deficiency anemia with the iron saturation of <20% which 4 (29%) of them received ESA. Conclusion: Most of patients' leukocyte and platelets levels were normal. Patients who received ESA had higher Hb levels. Platelets levels had a reverse correlation with the longer period of hemodialysis.
Mean Platelet Volume Predicts Vascular Access Events in Hemodialysis Patients
Journal of Clinical Medicine, 2019
Arteriovenous fistula (AVF) and arteriovenous graft (AVG) is the vascular access (VA) of 78% of hemodialysis patients (HD) in France. VA dysfunction corresponding to either stenosis requiring angioplasty or acute thrombosis is responsible for 30% of hospitalizations. Mean platelet volume (MPV) is a biological marker of cardiovascular events. We studied MPV in a cohort of HD patients as a predictive marker of VA dysfunction. We conducted a prospective monocentric cohort study that included patients with AVF or AVG on chronic HD (n = 153). The primary outcome was the incidence of VA dysfunction regarding MPV value. The median MPV was 10.8 fL (7.8–13.5), and four groups were designed according to MPV quartiles. Fifty-four patients experienced the first event of VA dysfunction. The incidence of VA dysfunction was higher in patients with the highest MPV: 59% (23 events), 34% (14 events), 27% (11 events), and 18% (6 events), respectively, for the fourth, third, second, and first quartiles...
American Journal of Clinical Nutrition, 2011
Background: It is not clear why cardiac or renal cachexia in chronic diseases is associated with poor cardiovascular outcomes. Platelet reactivity predisposes to thromboembolic events in the setting of atherosclerotic cardiovascular disease, which is often present in patients with end-stage renal disease (ESRD). Objectives: We hypothesized that ESRD patients with relative thrombocytosis (platelet count .300 · 10 3 /lL) have a higher mortality rate and that this association may be related to malnutritioninflammation cachexia syndrome (MICS). Design: We examined the associations of 3-mo-averaged platelet counts with markers of MICS and 6-y all-cause and cardiovascular mortality (2001)(2002)(2003)(2004)(2005)(2006)(2007) in a cohort of 40,797 patients who were receiving maintenance hemodialysis. Results: The patients comprised 46% women and 34% African Americans, and 46% of the patients had diabetes. The 3-mo-averaged platelet count was 229 6 78 · 10 3 /lL. In unadjusted and case-mix adjusted models, lower values of albumin, creatinine, protein intake, hemoglobin, and dialysis dose and a higher erythropoietin dose were associated with a higher platelet count. Compared with patients with a platelet count of between 150 and 200 · 10 3 /lL (reference), the allcause (and cardiovascular) mortality rate with platelet counts between 300 and ,350, between 350 and ,400, and !400 ·10 3 /lL were 6% (and 7%), 17% (and 15%), and 24% (and 25%) higher (P , 0.05), respectively. The associations persisted after control for case-mix adjustment, but adjustment for MICS abolished them. Conclusions: Relative thrombocytosis is associated with a worse MICS profile, a lower dialysis dose, and higher all-cause and cardiovascular disease death risk in hemodialysis patients; and its all-cause and cardiovascular mortality predictability is accounted for by MICS.
Bangladesh Journal of Medicine, 2013
This observational study was done on 50 cases of predialytic chronic kidney disease (CKD) patients. The aim of the study was to determination of total platelet count and bleeding time, comparison of the platelet count and bleeding time with the severity of chronic kidney disease. The mean age of the patients was 41.22±2.0 years, mean haemoglobin 4.96 ±0.32gm/dl, serum creatinine430.74± 11.92 ?mol/L, platelet count 246.50 ± 13.63x109/L and bleeding time were 4.13± 0.28 min respectively. Thrombocytopenia (<150x109/L) were found in 19(38%) cases. Bleeding time was prolonged (>9min) 6(12%) cases , among them only 4(8% ) cases were thrombocytopenic. There was no significant relationship between platelet count and serum creatinine. No correlation was found between platelet count and bleeding time. No significant correlation was also found in Bleeding time and creatinine. Therefore, it can be concluded that platelet count is highly variable in chronic kidney disease and it is not a r...
Journal of Drug Delivery and Therapeutics
Background: Chronic renal failure is a global public health problem; Kidney transplantation and dialysis are possible solutions of kidney failure. The aim of our study was to assess the platelet count, platelet indices, prothrombin time (PT) and partial thromboplastin time (PTT) in Sudanese chronic renal failure patients at Khartoum sate, 2022. Materials and Method: This was analytical case control study conducted at Khartoum state. A total of 200 blood samples were collected (100 samples from chronic renal failure patients and 100 healthy individuals from control group). A total of five ml of whole blood was collected from each participant and divided into EDTA anticoagulated tube for platelet count and platelet indices, and into sodium citrate anticoagulated tube. for PT and PTT measurement. Examination of platelet count and platelet indices was done by using Haematology analyser (Sysmex-XP-300), where PT and APTT measurement was done by using coagulation analyser (Coatron-M-1). ...
2016
Objective: Chronic kidney disesase (CKD) is a state of atherosclerotic and chronic inflammation and as the estimated glomerular filtration rate (GFR) declines, cardiovascular disease (CVD) risk and inflammation increase. Mean platelet volume (MPV) has shown to be influenced by cardiovascular risk factors. The aim of this study was to evaluate the relationship between MPV and CKD. Methods: This is prospective study of a total of 812 CKD patients. Patients with CKD were assigned to into the five groups depending on estimated GFR which were calculated by Modification of Diet in Renal Disease (MDRD). Patients demographics, comorbid disease were recorded, and laboratory variables were also evaluated. Results: The mean age of CKD patients was 62.6±15.4 years. According to stages, 96 patients (11.8%) were classified as stage 1 (GFR >90 ml/min/1.73 m 2), 77 patients (9.5%) as stage 2 (GFR 89-60 ml/min/1.73 m 2), 306 patients (37.7%) as stage 3 (GFR 59-30 ml/min/1.73 m 2), 198 (24.4%) pat...